Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8631773 | 1.00 | HIF1A (0.43) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL8698710 | 1.00 | HIF1A (0.43) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL8698714 | 1.00 | HIF1A (0.43) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL14407774 | 1.00 | HIF1A (0.43) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL1190325 | 0.89 | — | — | |
| SCHEMBL1190367 | 0.89 | — | — | |
| SCHEMBL1190324 | 0.89 | — | — | |
| SCHEMBL1190366 | 0.89 | — | — | |
| SCHEMBL14900784 | 0.89 | ALPL (0.36) | MAPTALPLL3MBTL1 | |
| Hydrochloric Acid SCHEMBL30106556 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210008031-A1 | SUPER-OXIDE DISMUTASE MIMETICS | KEREOS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20190328704-A1 | SUPER-OXIDE DISMUTASE MIMETICS | KEREOS, INC. | 2019-10-31 | — | — | US | disclosed |
| US-10350193-B2 | Super-oxide dismutase mimetics | GALERA LABS, LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-20160263085-A1 | SUPER-OXIDE DISMUTASE MIMETICS | KEREOS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9353069-B2 | Super-oxide dismutase mimetics | GALERA LABS, LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-8486928-B2 | Super-oxide dismutase mimetics | GALERA THERAPEUTICS (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100256178-A1 | SUPER-OXIDE DISMUTASE MIMETICS | GALERA LABS, LLC | 2010-10-07 | — | — | US | disclosed |
| US-20090131377-A1 | Combinations of Superoxide Dismutase Mimetics and Nonsteroidal Analgesic/Anti-Inflammatory Drugs | METAPHORE PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2006083508-A2 | COMBINATIONS OF SUPEROXIDE DISMUTASE MIMETICS AND NONSTEROIDAL ANALGESIC/ANTI-INFLAMMATORY DRUGS | METAPHORE PHARMACEUTICALS INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20050171198-A1 | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease | METAPHORE PHARMACEUTICALS, INC. | 2005-08-04 | — | — | US | disclosed |
| US-20050171198-A1 | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease | METAPHORE PHARMACEUTICALS, INC. | 2005-08-04 | — | — | US | disclosed |
| US-5721361-A | CONTACTING A DIAMINE OR TRIAMINE AND A DICARBOXYLIC ACID OR ESTER IN THE PRESENCE OF A BASE AND SOLVENT; COUPLING AGENT; REDUCTION; COMPLEXING WITH MANGANESE COMPOUNDS; ION EXCHANGING | THE MONSANTO COMPANY (US) | 1998-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171198-A1 | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease | SOD1, MPO, SOD3 | HIF1A 2152/4885MAPT 3249/4885PDE4A 2500/4885 |
| US-20190328704-A1 | SUPER-OXIDE DISMUTASE MIMETICS | SOD1, SOD3, CAT | HIF1A 1196/4885MAPT 3561/4885PDE4A 2471/4885 |
| US-10350193-B2 | Super-oxide dismutase mimetics | SOD1, SOD3, CAT | HIF1A 1184/4885MAPT 3556/4885PDE4A 2549/4885 |
| US-20100256178-A1 | SUPER-OXIDE DISMUTASE MIMETICS | SOD1, SOD3, CAT | HIF1A 1184/4885MAPT 3556/4885PDE4A 2549/4885 |
| US-20090131377-A1 | Combinations of Superoxide Dismutase Mimetics and Nonsteroidal Analgesic/Anti-Inflammatory Drugs | SOD1, SOD3, CAT | HIF1A 864/4885MAPT 3634/4885PDE4A 1035/4885 |
| US-20160263085-A1 | SUPER-OXIDE DISMUTASE MIMETICS | SOD1, SOD3, CAT | HIF1A 1184/4885MAPT 3556/4885PDE4A 2549/4885 |
| US-20210008031-A1 | SUPER-OXIDE DISMUTASE MIMETICS | SOD1, SOD3, CAT | HIF1A 1196/4885MAPT 3561/4885PDE4A 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.